Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016 USD ($) Subsidiary shares	Dec. 31, 2015 USD ($) shares	Dec. 31, 2014 USD ($) shares	Dec. 31, 2013 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Wholly-owned subsidiaries of Antares Pharma | Subsidiary	2
Bad debt expense	$ 0	$ 0	$ 37,000
Allowance for doubtful accounts balance	10,000	10,000
Inventory reserve	900,000	800,000
Inventory written-off	650,000	3,500,000
Increase in inventory reserve	748,378	700,000	3,550,000
Depreciation expense	1,326,378	1,034,057	880,400
Patent rights	4,659,103	4,533,439
Accumulated amortization of patents	2,614,495	2,098,897
Aggregate patent amortization expense, 2017	541,000
Aggregate patent amortization expense, 2018	541,000
Aggregate patent amortization expense, 2019	311,000
Aggregate patent amortization expense, 2020	92,000
Aggregate patent amortization expense, 2021	71,000
Amortization expense	534,304	535,791	343,817
Patent write off	0	31,501	0
Goodwill	1,095,355	1,095,355
Goodwill impairment loss	0	0	0
Short-term investments	0	15,012,225
Product revenue	$ 40,318,339	27,533,042	$ 13,195,577
Cash discount to incentive for prompt payment	2.00%
Method used for fair value assumption	Black-Scholes option valuation model
Warranty period of device	24 months
Warranty liability reserves	$ 100,000	$ 100,000
Potentially dilutive securities excluded from dilutive loss per share | shares	11,313,909	9,480,497	7,245,485
Cash and cash equivalents	$ 27,714,588	$ 32,898,676	$ 34,028,889	$ 39,067,236
Accounting Standards Update 2014-15 [Member]
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents	27,714,588
Debt obligations	$ 0
Teva [Member]
Summary Of Significant Accounting Policies [Line Items]
Future net profits from commercial sales percent	50.00%
OTREXUP [Member]
Summary Of Significant Accounting Policies [Line Items]
Product revenue	$ 15,145,214	13,249,715	$ 7,309,603
Deferred revenue balance	$ 1,670,220	$ 1,064,874
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	3 years
Capitalized cost being amortized over periods	5 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	10 years
Capitalized cost being amortized over periods	15 years